Canaccord Genuity Maintains Buy on Teladoc Health, Raises Price Target to $11
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and raises the price target from $10 to $11.
Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and raises the price target from $10 to $11.